Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10430874 | 1.00 | MEN1 (0.42) | MEN1KMT2ACREBBPKDM4CNPC1 | |
| SCHEMBL9680069 | 0.89 | MEN1 (0.46) | MEN1KMT2ACREBBPKDM4CNPC1 | |
| SCHEMBL26645794 | 0.83 | KMT2A (0.40) | MEN1KMT2AKDM4C | |
| SCHEMBL11864616 | 0.83 | MEN1 (0.40) | MEN1KMT2ACREBBPKDM4CNPC1 | |
| SCHEMBL9655459 | 0.83 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1ICAM1 | |
| SCHEMBL3816272 | 0.82 | KMT2A (0.43) | MEN1KMT2ACREBBPKDM4CNPC1 | |
| SCHEMBL20837278 | 0.82 | MGAM (0.39) | MEN1KMT2ACREBBPNPC1RAB9A | |
| SCHEMBL3030136 | 0.80 | MEN1 (0.48) | MEN1KMT2ACREBBPKDM4CEP300 | |
| SCHEMBL374442 | 0.80 | KMT2A (0.44) | MEN1KMT2ACREBBPNPC1RAB9A | |
| SCHEMBL17424231 | 0.79 | MEN1 (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382946-A1 | POLYPEPTIDE OR PROTEIN DIRECTIONAL MODIFICATION METHOD BASED ON SULFHYDRYL-ALKENYL AZIDE COUPLING | Changzhou University (CN) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382946-A1 | POLYPEPTIDE OR PROTEIN DIRECTIONAL MODIFICATION METHOD BASED ON SULFHYDRYL-ALKENYL AZIDE COUPLING | PTMS, CBS, CHAMP1 | MEN1 2995/4885KMT2A 4327/4885CREBBP 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.